Abstracts Thirty‐Seventh Annual Meeting American College of Clinical Pharmacology September 14–16, 2008 Philadelphia, Pennsylvania
Identifieur interne : 001625 ( Main/Curation ); précédent : 001624; suivant : 001626Abstracts Thirty‐Seventh Annual Meeting American College of Clinical Pharmacology September 14–16, 2008 Philadelphia, Pennsylvania
Auteurs :Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2008-09.
English descriptors
- Teeft :
- Abso, Abso rption, Absorption rate, Active metabo lite, Admi, Admi nistered, Admi nistration, Admin, Admission units, Adult oncology patients, Adverse events, Afte, Alcohol abuse, Aliskiren, Anal, Anal ysis, Anal yzed, Analy, Apix aban, Apixaban, Apixaban phase, Apixaban plasma concentration, Apparent clearan, Apparent clearance, Apparent volume, Approxima tely, Armoda finil, Aromatic alkaloids, Assay, Asse ssed, Asthma patients, Ation, Barrett, Base line, Baseline, Baseline disease activity, Baseline hepatic, Bhuvana jayaraman, Bhuvana jayararnan, Bile collection, Bioavailability, Biomarker, Biomarkers, Bjects, Blood pressure, Blood samp, Blood sample, Blood samples, Body weig, Body weight, Bolus dose, Caffeine, Caffeine concentration, Caffeine concentrations, Caffeine content, Calcul ated, Carbonated sodas, Cardiac, Cardiovascular diseases, Caso pitant, Central compartment, Cgmp, Charac terized, Chil dren, Cigarette smoke, Clea rance, Clearan, Clearance, Clin, Clin ically, Clin pharmacol, Clinic, Clinica, Clinical epidem iology, Clinical epidemiology, Clinical evaluation, Clinical flare, Clinical investigation, Clinical pharmacology, Clinical smoking dependence, Coadministration, Cognitive functions, Comb ination, Combina tion, Compartment model, Conc, Conce, Concentra, Concl usion, Conclus, Conclus ions, Concomitant, Concomitant medications, Cond itions, Confidence interval, Confidence intervals, Cons ists, Contro, Coso lvents, Covariate, Covariates, Creatinine, Creatinine clearance, Crossover, Crossover design, Crossover study, Ction, Daiichi sankyo, Daily dose, Dapa gliflozin, Data base, Data types, Database, Demographic characteristics, Depression disease, Design synthesis, Determ ined, Deve, Develo pment, Developmental changes, Diabetes mellitus, Differe, Dimple patel, Direct factor, Discovery medicine, Distribu tion, Dos, Dose, Dose administration, Dose level, Dose range, Dose regimen, Dose selection, Dose studies, Dose study, Dosing, Dosing regimen, Dosing requirements, Drug administration, Drug safety, Drug therapy, Drug utilization, Ect, Effec, Effect model, Efficacy outcomes, Emax models, Endo morphin, Enfennedades respiratorias, Ents, Erythrocyte sedimentation rate, Estab lished, Estima, Ethods, Etoricoxib, Excretion, Expo, Expos ures, Exposure model, Extension trial, Ferulic acid, Ffects modeling, Fibrinogen, Final model, Final population, Finil, First order absorption, First time, First year, Foll, Forecasting algorithm, Future studies, Gaba pentin, Gabape ntin, Gabapentin, Gabapentin exposu, Gabapentin exposure, Gender, Gender differences, Gender distribution, Geome tric, Glom eruli, Good source, Great valley parkway, Grou, Hartmut derendorf, Healthy adult smokers, Healthy adults, Healthy population, Healthy subj ects, Healthy subjects, Healthy volunteers, Heart rate, Hosp ital, Hospital admission, Hplc method, Huma, Iatric, Iatric patient, Ical, Icine, Ients, Ification drop, Ility, Important role, Incl, Incl uded, Ined, Inflamm ation, Informatics system, Infusion, Inhi bitor, Inhibitor, Instituto nacional, Inte, Intercompartmental clearance, Interethnic differences, Intestinal tract, Inves tigated, Invo lved, Ived, Ized, Jeffrey, Kine tics, Knopp neurosciences, Lation, Least squares, Lebo witz, Lerab ility, Leve, Ling, Linical pharmacology, Logistic regression, Logy, Lonnie rimmer, Lowe, Lower concentration, Lthy, Luated, Lysis, Mahesh narayan, Marc pfister, Mass balance, Mayo, Mayo clinic, Mechan isms, Median, Medical need, Medication, Medicine rochester, Meeting abstracts, Meloxicam, Ment, Merck, Merck research laboratories, Metab olism, Metabo, Metabolism, Meth, Mexico city, Mglkg, Mild dizziness, Mina tion, Ministra tion, Moda finil, Mode ling, Modeling, Mountain view, Mouse model, Mpared, Msec, Multiple doses, Naproxen, National institute, Natriuretic, Nclus ions, Neon ates, Nitive functions, Noncompartmental methods, Nonmem, Normal doses, Nove, Novel diagnostics, Novel peptide, Ntly, Ntra, Ntra tions, Obatoclax, Obese, Obese patients, Obse, Observational study, Obta ined, Oncology, Open heart surgery, Openlabel study, Oral contraceptives, Oral corticosteroids, Oral doses, Oral dosing, Oral pharmacokinetics, Other populations, Oxidative stress, Para, Para meters, Parame ters, Parameter, Pathway, Pati, Pati ents, Patie, Patien, Pediatric, Pediatric health care professionals, Pediatric patients, Pennsylvania school, Peptide, Peripheral volume, Pharm, Pharma, Pharma cokinetics, Pharma cology, Pharmaceutical, Pharmaco, Pharmaco kinetics, Pharmacokine tics, Pharmacokinetic, Pharmacokinetic parameters, Pharmacokinetics, Pharmacol, Pharmacology, Pharmacotherapy, Pharmacotherapy guidance, Pkjpd, Pkjpd modeling, Pklpd, Pklpd simulation, Placebo, Placebo infusion, Placebo patch, Plasma, Plasma concentration, Plasma concentrations, Plasma levels, Plasma samples, Popu, Popu lation, Popula tion, Population pharma cokinetics, Positive control, Possible covariates, Potential biomarkers, Pred, Predictive tool, Prednisolone tablet, Present study, Probe drug, Pulse wave velocity, Query, Random ized, Randomized, Rece, Rece ived, Recep, Receptor, Receptor antagonist, Receptor occupancy, Records system, Regimen, Rela tionship, Renal, Renal clearance, Renal funct, Renal functions, Renin, Repo rting, Research center, Residual, Residual variability, Respe ctively, Respec tively, Response rate, Resu, Resul, Rheumatoid arthritis, Ribavirin, Risk factors, Ritonavir, Rivo, Rivo tablets, Robin blumenthal, Robust predictions, Same doses, Sample size, Sampling design, Sankyo, Santa clara, Scenario, Secondary prevention, Seminal vesicle, Sequential, Sequential groups, Sick children, Side effects, Sign ifica, Signi, Signi fica ntly, Signi ficantly, Signific antly, Significan, Significant covariate, Significant covariates, Significant difference, Significant effect, Simulation, Simulation model, Single center, Single dose, Smoker, Smoking dependence, Smoking status, Solabegron exposure, Sparse samples, Sparse sampling, Spinal cord tissue, Standard dose, State university, Statin, Steady state, Stress parameters, Study logistics, Subcu taneous, Subcutaneous, Subcutaneous adipo, Subj, Subj ects, Subje, Subjec, Suitable laboratory tests, Sunil kapur, Tablet, Tarek leil, Target population, Technical university, Testicular function, Therapeutics, Thma patients, Tic, Tients, Tile assay, Time course, Ting, Tion, Tions, Tive, Tment, Tolerab ility, Tolerability, Total error, Trans ient, Trea, Trea tment, Treatme, Trial simulator, Trospium, Trospium exposure, Tudy, Ubject variab ility, Uced, Ular, Ulation, Unive, Univers, University college, Upcoming phase, Upper bounds, Urinary, Urinary excretion, Urine, Urine flow, Urine samples, Vancomycin, Varia, Varia tion, Variab, Variab ility, Variability, Venla faxine, Virginia commonwealth university, Vital signs, Vivo, Vivo activity, Warfarin, Weight gain, Weight range, Whitehouse station, Wilhelm kirch.
Url:
DOI: 10.1177/00912700080480091001
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000925
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000890
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000175
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001629
Links to Exploration step
ISTEX:FEFFD0E0EA5DD8BC354E95FB067B58926CA15244Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abstracts Thirty‐Seventh Annual Meeting American College of Clinical Pharmacology September 14–16, 2008 Philadelphia, Pennsylvania</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FEFFD0E0EA5DD8BC354E95FB067B58926CA15244</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1177/00912700080480091001</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-TKRRHJPJ-B/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000925</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000925</idno>
<idno type="wicri:Area/Istex/Curation">000890</idno>
<idno type="wicri:Area/Istex/Checkpoint">000175</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000175</idno>
<idno type="wicri:Area/Main/Merge">001629</idno>
<idno type="wicri:Area/Main/Curation">001625</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Abstracts Thirty‐Seventh Annual Meeting American College of Clinical Pharmacology September 14–16, 2008 Philadelphia, Pennsylvania</title>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">The Journal of Clinical Pharmacology</title>
<title level="j" type="alt">JOURNAL OF CLINICAL PHARMACOLOGY</title>
<idno type="ISSN">0091-2700</idno>
<idno type="eISSN">1552-4604</idno>
<imprint><biblScope unit="vol">48</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1099">1099</biblScope>
<biblScope unit="page" to="1135">1135</biblScope>
<biblScope unit="page-count">37</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2008-09">2008-09</date>
</imprint>
<idno type="ISSN">0091-2700</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0091-2700</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abso</term>
<term>Abso rption</term>
<term>Absorption rate</term>
<term>Active metabo lite</term>
<term>Admi</term>
<term>Admi nistered</term>
<term>Admi nistration</term>
<term>Admin</term>
<term>Admission units</term>
<term>Adult oncology patients</term>
<term>Adverse events</term>
<term>Afte</term>
<term>Alcohol abuse</term>
<term>Aliskiren</term>
<term>Anal</term>
<term>Anal ysis</term>
<term>Anal yzed</term>
<term>Analy</term>
<term>Apix aban</term>
<term>Apixaban</term>
<term>Apixaban phase</term>
<term>Apixaban plasma concentration</term>
<term>Apparent clearan</term>
<term>Apparent clearance</term>
<term>Apparent volume</term>
<term>Approxima tely</term>
<term>Armoda finil</term>
<term>Aromatic alkaloids</term>
<term>Assay</term>
<term>Asse ssed</term>
<term>Asthma patients</term>
<term>Ation</term>
<term>Barrett</term>
<term>Base line</term>
<term>Baseline</term>
<term>Baseline disease activity</term>
<term>Baseline hepatic</term>
<term>Bhuvana jayaraman</term>
<term>Bhuvana jayararnan</term>
<term>Bile collection</term>
<term>Bioavailability</term>
<term>Biomarker</term>
<term>Biomarkers</term>
<term>Bjects</term>
<term>Blood pressure</term>
<term>Blood samp</term>
<term>Blood sample</term>
<term>Blood samples</term>
<term>Body weig</term>
<term>Body weight</term>
<term>Bolus dose</term>
<term>Caffeine</term>
<term>Caffeine concentration</term>
<term>Caffeine concentrations</term>
<term>Caffeine content</term>
<term>Calcul ated</term>
<term>Carbonated sodas</term>
<term>Cardiac</term>
<term>Cardiovascular diseases</term>
<term>Caso pitant</term>
<term>Central compartment</term>
<term>Cgmp</term>
<term>Charac terized</term>
<term>Chil dren</term>
<term>Cigarette smoke</term>
<term>Clea rance</term>
<term>Clearan</term>
<term>Clearance</term>
<term>Clin</term>
<term>Clin ically</term>
<term>Clin pharmacol</term>
<term>Clinic</term>
<term>Clinica</term>
<term>Clinical epidem iology</term>
<term>Clinical epidemiology</term>
<term>Clinical evaluation</term>
<term>Clinical flare</term>
<term>Clinical investigation</term>
<term>Clinical pharmacology</term>
<term>Clinical smoking dependence</term>
<term>Coadministration</term>
<term>Cognitive functions</term>
<term>Comb ination</term>
<term>Combina tion</term>
<term>Compartment model</term>
<term>Conc</term>
<term>Conce</term>
<term>Concentra</term>
<term>Concl usion</term>
<term>Conclus</term>
<term>Conclus ions</term>
<term>Concomitant</term>
<term>Concomitant medications</term>
<term>Cond itions</term>
<term>Confidence interval</term>
<term>Confidence intervals</term>
<term>Cons ists</term>
<term>Contro</term>
<term>Coso lvents</term>
<term>Covariate</term>
<term>Covariates</term>
<term>Creatinine</term>
<term>Creatinine clearance</term>
<term>Crossover</term>
<term>Crossover design</term>
<term>Crossover study</term>
<term>Ction</term>
<term>Daiichi sankyo</term>
<term>Daily dose</term>
<term>Dapa gliflozin</term>
<term>Data base</term>
<term>Data types</term>
<term>Database</term>
<term>Demographic characteristics</term>
<term>Depression disease</term>
<term>Design synthesis</term>
<term>Determ ined</term>
<term>Deve</term>
<term>Develo pment</term>
<term>Developmental changes</term>
<term>Diabetes mellitus</term>
<term>Differe</term>
<term>Dimple patel</term>
<term>Direct factor</term>
<term>Discovery medicine</term>
<term>Distribu tion</term>
<term>Dos</term>
<term>Dose</term>
<term>Dose administration</term>
<term>Dose level</term>
<term>Dose range</term>
<term>Dose regimen</term>
<term>Dose selection</term>
<term>Dose studies</term>
<term>Dose study</term>
<term>Dosing</term>
<term>Dosing regimen</term>
<term>Dosing requirements</term>
<term>Drug administration</term>
<term>Drug safety</term>
<term>Drug therapy</term>
<term>Drug utilization</term>
<term>Ect</term>
<term>Effec</term>
<term>Effect model</term>
<term>Efficacy outcomes</term>
<term>Emax models</term>
<term>Endo morphin</term>
<term>Enfennedades respiratorias</term>
<term>Ents</term>
<term>Erythrocyte sedimentation rate</term>
<term>Estab lished</term>
<term>Estima</term>
<term>Ethods</term>
<term>Etoricoxib</term>
<term>Excretion</term>
<term>Expo</term>
<term>Expos ures</term>
<term>Exposure model</term>
<term>Extension trial</term>
<term>Ferulic acid</term>
<term>Ffects modeling</term>
<term>Fibrinogen</term>
<term>Final model</term>
<term>Final population</term>
<term>Finil</term>
<term>First order absorption</term>
<term>First time</term>
<term>First year</term>
<term>Foll</term>
<term>Forecasting algorithm</term>
<term>Future studies</term>
<term>Gaba pentin</term>
<term>Gabape ntin</term>
<term>Gabapentin</term>
<term>Gabapentin exposu</term>
<term>Gabapentin exposure</term>
<term>Gender</term>
<term>Gender differences</term>
<term>Gender distribution</term>
<term>Geome tric</term>
<term>Glom eruli</term>
<term>Good source</term>
<term>Great valley parkway</term>
<term>Grou</term>
<term>Hartmut derendorf</term>
<term>Healthy adult smokers</term>
<term>Healthy adults</term>
<term>Healthy population</term>
<term>Healthy subj ects</term>
<term>Healthy subjects</term>
<term>Healthy volunteers</term>
<term>Heart rate</term>
<term>Hosp ital</term>
<term>Hospital admission</term>
<term>Hplc method</term>
<term>Huma</term>
<term>Iatric</term>
<term>Iatric patient</term>
<term>Ical</term>
<term>Icine</term>
<term>Ients</term>
<term>Ification drop</term>
<term>Ility</term>
<term>Important role</term>
<term>Incl</term>
<term>Incl uded</term>
<term>Ined</term>
<term>Inflamm ation</term>
<term>Informatics system</term>
<term>Infusion</term>
<term>Inhi bitor</term>
<term>Inhibitor</term>
<term>Instituto nacional</term>
<term>Inte</term>
<term>Intercompartmental clearance</term>
<term>Interethnic differences</term>
<term>Intestinal tract</term>
<term>Inves tigated</term>
<term>Invo lved</term>
<term>Ived</term>
<term>Ized</term>
<term>Jeffrey</term>
<term>Kine tics</term>
<term>Knopp neurosciences</term>
<term>Lation</term>
<term>Least squares</term>
<term>Lebo witz</term>
<term>Lerab ility</term>
<term>Leve</term>
<term>Ling</term>
<term>Linical pharmacology</term>
<term>Logistic regression</term>
<term>Logy</term>
<term>Lonnie rimmer</term>
<term>Lowe</term>
<term>Lower concentration</term>
<term>Lthy</term>
<term>Luated</term>
<term>Lysis</term>
<term>Mahesh narayan</term>
<term>Marc pfister</term>
<term>Mass balance</term>
<term>Mayo</term>
<term>Mayo clinic</term>
<term>Mechan isms</term>
<term>Median</term>
<term>Medical need</term>
<term>Medication</term>
<term>Medicine rochester</term>
<term>Meeting abstracts</term>
<term>Meloxicam</term>
<term>Ment</term>
<term>Merck</term>
<term>Merck research laboratories</term>
<term>Metab olism</term>
<term>Metabo</term>
<term>Metabolism</term>
<term>Meth</term>
<term>Mexico city</term>
<term>Mglkg</term>
<term>Mild dizziness</term>
<term>Mina tion</term>
<term>Ministra tion</term>
<term>Moda finil</term>
<term>Mode ling</term>
<term>Modeling</term>
<term>Mountain view</term>
<term>Mouse model</term>
<term>Mpared</term>
<term>Msec</term>
<term>Multiple doses</term>
<term>Naproxen</term>
<term>National institute</term>
<term>Natriuretic</term>
<term>Nclus ions</term>
<term>Neon ates</term>
<term>Nitive functions</term>
<term>Noncompartmental methods</term>
<term>Nonmem</term>
<term>Normal doses</term>
<term>Nove</term>
<term>Novel diagnostics</term>
<term>Novel peptide</term>
<term>Ntly</term>
<term>Ntra</term>
<term>Ntra tions</term>
<term>Obatoclax</term>
<term>Obese</term>
<term>Obese patients</term>
<term>Obse</term>
<term>Observational study</term>
<term>Obta ined</term>
<term>Oncology</term>
<term>Open heart surgery</term>
<term>Openlabel study</term>
<term>Oral contraceptives</term>
<term>Oral corticosteroids</term>
<term>Oral doses</term>
<term>Oral dosing</term>
<term>Oral pharmacokinetics</term>
<term>Other populations</term>
<term>Oxidative stress</term>
<term>Para</term>
<term>Para meters</term>
<term>Parame ters</term>
<term>Parameter</term>
<term>Pathway</term>
<term>Pati</term>
<term>Pati ents</term>
<term>Patie</term>
<term>Patien</term>
<term>Pediatric</term>
<term>Pediatric health care professionals</term>
<term>Pediatric patients</term>
<term>Pennsylvania school</term>
<term>Peptide</term>
<term>Peripheral volume</term>
<term>Pharm</term>
<term>Pharma</term>
<term>Pharma cokinetics</term>
<term>Pharma cology</term>
<term>Pharmaceutical</term>
<term>Pharmaco</term>
<term>Pharmaco kinetics</term>
<term>Pharmacokine tics</term>
<term>Pharmacokinetic</term>
<term>Pharmacokinetic parameters</term>
<term>Pharmacokinetics</term>
<term>Pharmacol</term>
<term>Pharmacology</term>
<term>Pharmacotherapy</term>
<term>Pharmacotherapy guidance</term>
<term>Pkjpd</term>
<term>Pkjpd modeling</term>
<term>Pklpd</term>
<term>Pklpd simulation</term>
<term>Placebo</term>
<term>Placebo infusion</term>
<term>Placebo patch</term>
<term>Plasma</term>
<term>Plasma concentration</term>
<term>Plasma concentrations</term>
<term>Plasma levels</term>
<term>Plasma samples</term>
<term>Popu</term>
<term>Popu lation</term>
<term>Popula tion</term>
<term>Population pharma cokinetics</term>
<term>Positive control</term>
<term>Possible covariates</term>
<term>Potential biomarkers</term>
<term>Pred</term>
<term>Predictive tool</term>
<term>Prednisolone tablet</term>
<term>Present study</term>
<term>Probe drug</term>
<term>Pulse wave velocity</term>
<term>Query</term>
<term>Random ized</term>
<term>Randomized</term>
<term>Rece</term>
<term>Rece ived</term>
<term>Recep</term>
<term>Receptor</term>
<term>Receptor antagonist</term>
<term>Receptor occupancy</term>
<term>Records system</term>
<term>Regimen</term>
<term>Rela tionship</term>
<term>Renal</term>
<term>Renal clearance</term>
<term>Renal funct</term>
<term>Renal functions</term>
<term>Renin</term>
<term>Repo rting</term>
<term>Research center</term>
<term>Residual</term>
<term>Residual variability</term>
<term>Respe ctively</term>
<term>Respec tively</term>
<term>Response rate</term>
<term>Resu</term>
<term>Resul</term>
<term>Rheumatoid arthritis</term>
<term>Ribavirin</term>
<term>Risk factors</term>
<term>Ritonavir</term>
<term>Rivo</term>
<term>Rivo tablets</term>
<term>Robin blumenthal</term>
<term>Robust predictions</term>
<term>Same doses</term>
<term>Sample size</term>
<term>Sampling design</term>
<term>Sankyo</term>
<term>Santa clara</term>
<term>Scenario</term>
<term>Secondary prevention</term>
<term>Seminal vesicle</term>
<term>Sequential</term>
<term>Sequential groups</term>
<term>Sick children</term>
<term>Side effects</term>
<term>Sign ifica</term>
<term>Signi</term>
<term>Signi fica ntly</term>
<term>Signi ficantly</term>
<term>Signific antly</term>
<term>Significan</term>
<term>Significant covariate</term>
<term>Significant covariates</term>
<term>Significant difference</term>
<term>Significant effect</term>
<term>Simulation</term>
<term>Simulation model</term>
<term>Single center</term>
<term>Single dose</term>
<term>Smoker</term>
<term>Smoking dependence</term>
<term>Smoking status</term>
<term>Solabegron exposure</term>
<term>Sparse samples</term>
<term>Sparse sampling</term>
<term>Spinal cord tissue</term>
<term>Standard dose</term>
<term>State university</term>
<term>Statin</term>
<term>Steady state</term>
<term>Stress parameters</term>
<term>Study logistics</term>
<term>Subcu taneous</term>
<term>Subcutaneous</term>
<term>Subcutaneous adipo</term>
<term>Subj</term>
<term>Subj ects</term>
<term>Subje</term>
<term>Subjec</term>
<term>Suitable laboratory tests</term>
<term>Sunil kapur</term>
<term>Tablet</term>
<term>Tarek leil</term>
<term>Target population</term>
<term>Technical university</term>
<term>Testicular function</term>
<term>Therapeutics</term>
<term>Thma patients</term>
<term>Tic</term>
<term>Tients</term>
<term>Tile assay</term>
<term>Time course</term>
<term>Ting</term>
<term>Tion</term>
<term>Tions</term>
<term>Tive</term>
<term>Tment</term>
<term>Tolerab ility</term>
<term>Tolerability</term>
<term>Total error</term>
<term>Trans ient</term>
<term>Trea</term>
<term>Trea tment</term>
<term>Treatme</term>
<term>Trial simulator</term>
<term>Trospium</term>
<term>Trospium exposure</term>
<term>Tudy</term>
<term>Ubject variab ility</term>
<term>Uced</term>
<term>Ular</term>
<term>Ulation</term>
<term>Unive</term>
<term>Univers</term>
<term>University college</term>
<term>Upcoming phase</term>
<term>Upper bounds</term>
<term>Urinary</term>
<term>Urinary excretion</term>
<term>Urine</term>
<term>Urine flow</term>
<term>Urine samples</term>
<term>Vancomycin</term>
<term>Varia</term>
<term>Varia tion</term>
<term>Variab</term>
<term>Variab ility</term>
<term>Variability</term>
<term>Venla faxine</term>
<term>Virginia commonwealth university</term>
<term>Vital signs</term>
<term>Vivo</term>
<term>Vivo activity</term>
<term>Warfarin</term>
<term>Weight gain</term>
<term>Weight range</term>
<term>Whitehouse station</term>
<term>Wilhelm kirch</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001625 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001625 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:FEFFD0E0EA5DD8BC354E95FB067B58926CA15244 |texte= Abstracts Thirty‐Seventh Annual Meeting American College of Clinical Pharmacology September 14–16, 2008 Philadelphia, Pennsylvania }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |